
€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Cydar Medical Ltd raises €10.5m in Series A financing
Besides Pembroke Venture Capital Trust as cornerstone investor with €3.7m (£3m), new investor Downing LLP and existing seed investors supported the...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

Hummingbird and Synaffix in $150m ADC deal
Under the deal, Synaffix can earn up to $150m, including upfront and milestone payments, plus royalties on net sales if the ADC resulting from the...

German HTGF IV fund closes at €493m
Alongside the Federal Ministry of Economics and Climate Protection (BMWK) and KfW Capital, 45 private investors (companies) participated in HTGF IV...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...